PL4058151T3 - Nowa sól związku terfenylowego - Google Patents
Nowa sól związku terfenylowegoInfo
- Publication number
- PL4058151T3 PL4058151T3 PL20886261.5T PL20886261T PL4058151T3 PL 4058151 T3 PL4058151 T3 PL 4058151T3 PL 20886261 T PL20886261 T PL 20886261T PL 4058151 T3 PL4058151 T3 PL 4058151T3
- Authority
- PL
- Poland
- Prior art keywords
- novel salt
- terphenyl compound
- terphenyl
- compound
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934923P | 2019-11-13 | 2019-11-13 | |
| PCT/JP2020/042383 WO2021095835A1 (en) | 2019-11-13 | 2020-11-13 | Novel salt of terphenyl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4058151T3 true PL4058151T3 (pl) | 2025-08-04 |
Family
ID=75912767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20886261.5T PL4058151T3 (pl) | 2019-11-13 | 2020-11-13 | Nowa sól związku terfenylowego |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12419858B2 (pl) |
| EP (2) | EP4058018A4 (pl) |
| JP (2) | JP7379680B2 (pl) |
| KR (2) | KR20220113390A (pl) |
| CN (2) | CN114728899B (pl) |
| AU (2) | AU2020382379B2 (pl) |
| BR (2) | BR112022009221A2 (pl) |
| CA (2) | CA3157404A1 (pl) |
| DK (1) | DK4058151T3 (pl) |
| ES (1) | ES3034158T3 (pl) |
| FI (1) | FI4058151T3 (pl) |
| HU (1) | HUE072206T2 (pl) |
| MX (2) | MX2022005811A (pl) |
| PH (2) | PH12022551169A1 (pl) |
| PL (1) | PL4058151T3 (pl) |
| PT (1) | PT4058151T (pl) |
| TW (2) | TWI874490B (pl) |
| WO (2) | WO2021095835A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| PL4058151T3 (pl) | 2019-11-13 | 2025-08-04 | Taiho Pharmaceutical Co., Ltd. | Nowa sól związku terfenylowego |
| WO2022214303A1 (en) | 2021-04-08 | 2022-10-13 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| CN117769540A (zh) * | 2021-05-11 | 2024-03-26 | 亚士德制药公司 | 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 |
| KR20240065302A (ko) * | 2021-09-30 | 2024-05-14 | 다이호야쿠힌고교 가부시키가이샤 | 비페닐 화합물 및 면역 체크포인트 분자 조절제를 사용한 암에 대한 조합 요법 |
| JP7788550B2 (ja) * | 2021-10-26 | 2025-12-18 | 大鵬薬品工業株式会社 | ターフェニル化合物の安息香酸塩の製造方法 |
| JP2025516647A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| AU2024265282A1 (en) * | 2023-05-02 | 2025-12-18 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801518D0 (sv) * | 1988-04-22 | 1988-04-22 | Astra Pharma Prod | A novel process |
| US6225049B1 (en) | 1992-06-17 | 2001-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Human insulinoma-associated cDNA |
| AU2002357191A1 (en) | 2001-12-13 | 2003-06-30 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
| EP1792622A1 (en) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
| WO2010017047A1 (en) | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Therapeutic compounds |
| WO2010048123A2 (en) | 2008-10-20 | 2010-04-29 | Eckhardt S Gail | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US8367679B2 (en) | 2008-12-09 | 2013-02-05 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
| WO2010120966A1 (en) | 2009-04-17 | 2010-10-21 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| PL2560949T3 (pl) | 2010-04-20 | 2017-01-31 | Università Degli Studi Di Roma "La Sapienza" | Pochodne tranylocyprominy jako inhibitory demetylazy histonowej LSD1 i/lub LSD2 |
| PL2598482T3 (pl) | 2010-07-29 | 2018-10-31 | Oryzon Genomics, S.A. | Inhibitory demetylazy lsd1 na bazie arylocyklopropyloaminy i ich zastosowanie medyczne |
| EP2711704B1 (en) | 2011-05-16 | 2017-06-28 | Taiho Pharmaceutical Co., Ltd. | Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor |
| WO2013057320A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CN113521093A (zh) * | 2012-05-09 | 2021-10-22 | 坎泰克斯制药股份有限公司 | 骨髓抑制的治疗 |
| EP2968358A4 (en) | 2013-03-15 | 2016-08-10 | Ariad Pharma Inc | NOVEL CHOLINKINASE INHIBITORS |
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| US9266907B2 (en) | 2013-09-05 | 2016-02-23 | King Abdullah University Of Science And Technology | Tunable rare-earth fcu-metal-organic frameworks |
| LT3080100T (lt) | 2013-12-11 | 2023-02-27 | Celgene Quanticel Research, Inc. | Lizinui specifinės demetilazės-1 inhibitoriai |
| AU2014374043B2 (en) | 2014-01-06 | 2019-06-27 | Algomedix, Inc. | TRPA1 modulators |
| RS62874B1 (sr) | 2014-05-01 | 2022-02-28 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| CN107106517A (zh) | 2014-08-25 | 2017-08-29 | 堪培拉大学 | 用于调节癌干细胞的组合物及其用途 |
| SG11201701683XA (en) | 2014-09-05 | 2017-04-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
| KR102891799B1 (ko) | 2015-04-20 | 2025-11-26 | 이펙터 테라퓨틱스, 인크. | 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| DK3381896T3 (da) * | 2015-11-27 | 2023-03-27 | Taiho Pharmaceutical Co Ltd | Biphenylforbindelse eller salt deraf |
| WO2018136961A1 (en) | 2017-01-23 | 2018-07-26 | Syros Pharmaceuticals Inc. | METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY |
| KR102361918B1 (ko) * | 2017-05-26 | 2022-02-14 | 다이호야쿠힌고교 가부시키가이샤 | 신규 비페닐 화합물 또는 그의 염 |
| WO2018216795A1 (ja) | 2017-05-26 | 2018-11-29 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| AU2018276611B2 (en) * | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| DK3644999T3 (da) | 2017-06-30 | 2023-03-06 | Celgene Corp | Sammensætninger og fremgangsmåder til anvendelse af 2-(4-chlorphenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoracetamid |
| WO2019075327A1 (en) | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF MERKEL CELL CARCINOMA |
| US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| US20210186905A1 (en) | 2017-11-29 | 2021-06-24 | EpiAxis Therapeutic Pty Ltd | Enhancing t-cell function and treating a t-cell dysfunctional disorder with a combination of an lsd inhibitor and a pd-1 binding antagonist |
| EP3735243A4 (en) | 2018-01-02 | 2021-08-25 | Celgene Corporation | ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE |
| BR112022000484A2 (pt) | 2019-07-17 | 2022-03-08 | Summit Oxford Ltd | Processo de preparação de ridinilazol e formas cristalinas do mesmo |
| PL4058151T3 (pl) | 2019-11-13 | 2025-08-04 | Taiho Pharmaceutical Co., Ltd. | Nowa sól związku terfenylowego |
| US20230089536A1 (en) | 2020-03-06 | 2023-03-23 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
-
2020
- 2020-11-13 PL PL20886261.5T patent/PL4058151T3/pl unknown
- 2020-11-13 DK DK20886261.5T patent/DK4058151T3/da active
- 2020-11-13 MX MX2022005811A patent/MX2022005811A/es unknown
- 2020-11-13 ES ES20886261T patent/ES3034158T3/es active Active
- 2020-11-13 US US17/775,795 patent/US12419858B2/en active Active
- 2020-11-13 WO PCT/JP2020/042383 patent/WO2021095835A1/en not_active Ceased
- 2020-11-13 JP JP2022519478A patent/JP7379680B2/ja active Active
- 2020-11-13 JP JP2022527859A patent/JP7492002B2/ja active Active
- 2020-11-13 AU AU2020382379A patent/AU2020382379B2/en active Active
- 2020-11-13 CN CN202080078991.9A patent/CN114728899B/zh active Active
- 2020-11-13 PH PH1/2022/551169A patent/PH12022551169A1/en unknown
- 2020-11-13 WO PCT/JP2020/042410 patent/WO2021095840A1/en not_active Ceased
- 2020-11-13 US US17/775,800 patent/US20220387384A1/en active Pending
- 2020-11-13 PH PH1/2022/551137A patent/PH12022551137A1/en unknown
- 2020-11-13 PT PT208862615T patent/PT4058151T/pt unknown
- 2020-11-13 EP EP20886658.2A patent/EP4058018A4/en active Pending
- 2020-11-13 AU AU2020382214A patent/AU2020382214B2/en active Active
- 2020-11-13 KR KR1020227019783A patent/KR20220113390A/ko not_active Ceased
- 2020-11-13 TW TW109139813A patent/TWI874490B/zh active
- 2020-11-13 BR BR112022009221A patent/BR112022009221A2/pt unknown
- 2020-11-13 FI FIEP20886261.5T patent/FI4058151T3/fi active
- 2020-11-13 HU HUE20886261A patent/HUE072206T2/hu unknown
- 2020-11-13 EP EP20886261.5A patent/EP4058151B1/en active Active
- 2020-11-13 CA CA3157404A patent/CA3157404A1/en active Pending
- 2020-11-13 TW TW109139799A patent/TWI874489B/zh active
- 2020-11-13 KR KR1020227019781A patent/KR102825246B1/ko active Active
- 2020-11-13 MX MX2022005812A patent/MX2022005812A/es unknown
- 2020-11-13 BR BR112022008020A patent/BR112022008020A2/pt unknown
- 2020-11-13 CA CA3158442A patent/CA3158442A1/en active Pending
- 2020-11-13 CN CN202080079021.0A patent/CN114828844A/zh active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4058151T3 (pl) | Nowa sól związku terfenylowego | |
| GB201902327D0 (en) | Novel compounds | |
| GB201806578D0 (en) | Novel compound | |
| GB201912674D0 (en) | Novel compounds | |
| GB201905371D0 (en) | Novel compounds | |
| GB201918587D0 (en) | Novel compounds | |
| SG11202107528PA (en) | Pyrimidine compound or salt thereof | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| IL289627A (en) | New compounds inhibit pfar | |
| GB201913548D0 (en) | Novel compounds | |
| GB201913767D0 (en) | Luminescent compounds | |
| GB201908424D0 (en) | Novel compounds | |
| GB201910665D0 (en) | Novel form of compounds | |
| IL277578A (en) | New salt forms of URAT-1 inhibitors | |
| IL276195A (en) | Salt forms of an organic compound | |
| GB201910664D0 (en) | Novel forms of compound | |
| GB201910666D0 (en) | Novel form of compounds | |
| GB201804905D0 (en) | Cataltic synthesis of biarylic compounds | |
| GB201918076D0 (en) | Novel compounds | |
| GB201917863D0 (en) | Novel compounds | |
| GB201917320D0 (en) | Novel compounds | |
| GB201915129D0 (en) | Novel compounds | |
| GB201914623D0 (en) | Novel compounds | |
| GB201914624D0 (en) | Novel compounds | |
| GB201912865D0 (en) | Novel compounds |